Trial Profile
Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- 20 Mar 2015 New trial record